AstraZeneca stock jumps 4% after surprise lung disease trial win

AstraZeneca stock jumps 4% after surprise lung disease trial win

AstraZeneca‘s stock jumped as much as 4% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former smokers and in the overall population versus placebo, the company said. “This marks a notable…

Read More